Neumora Therapeutics (NASDAQ:NMRA) Reaches New 12-Month High After Analyst Upgrade

Neumora Therapeutics, Inc. (NASDAQ:NMRA) shares hit a new 52-week high during trading on Wednesday after William Blair upgraded the stock from a market perform rating to an outperform rating. The company traded as high as $3.64 and last traded at $3.54, with a volume of 2286850 shares trading hands. The stock had previously closed at $3.20.

Several other equities analysts have also issued reports on NMRA. Needham & Company LLC boosted their price target on Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Royal Bank Of Canada upgraded shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $7.00 in a research note on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. Mizuho set a $6.00 target price on Neumora Therapeutics in a report on Monday, January 5th. Finally, Stifel Nicolaus raised their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.13.

Insider Activity

In other news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. The trade was a 0.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 23,387 shares of company stock valued at $82,647 in the last three months. Insiders own 26.80% of the company’s stock.

Key Stories Impacting Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: William Blair upgraded Neumora, raising the firm’s rating on NMRA — this analyst move drove buying interest and was reported across outlets. William Blair upgrade
• Positive Sentiment: Following the upgrade, NMRA shares gapped up and hit a new 52-week high — a technical/market reaction that can attract momentum buyers. Shares gap up / 52-week high
• Neutral Sentiment: Recent trading context: volume is below its 3-month average, market cap is roughly $581M, the shares have high short-term volatility (beta ~3.2) and the company shows strong current/quick ratios — these fundamentals provide context but aren’t a single directional catalyst.
• Negative Sentiment: Insider sale — Michael Lee Milligan sold 1,436 shares at ~$3.56 (filed 2/17). This reduced his stake by ~6.4%, which can be viewed negatively by the market. Milligan Form 4
• Negative Sentiment: Insider sale — Paul L. Berns sold 9,819 shares at ~$3.51 (filed 2/17), a small percentage reduction of a large position; notable due to size. Berns Form 4
• Negative Sentiment: Insider sale — President Joshua Pinto sold 5,967 shares at ~$3.54 (filed 2/17), a ~9.4% cut in his holdings; insider selling by an executive is often viewed unfavorably. Pinto Form 4
• Negative Sentiment: Insider sale — Daljit Singh Aurora sold 6,165 shares at ~$3.56 (filed 2/17), trimming his stake by ~6.9%; multiple contemporaneous insider sales amplify perceived negative signal. Aurora Form 4

Institutional Trading of Neumora Therapeutics

Several large investors have recently made changes to their positions in NMRA. Invesco Ltd. increased its stake in shares of Neumora Therapeutics by 23.8% in the fourth quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock valued at $407,000 after buying an additional 43,795 shares in the last quarter. XTX Topco Ltd acquired a new stake in Neumora Therapeutics in the 4th quarter valued at about $204,000. Ikarian Capital LLC raised its stake in shares of Neumora Therapeutics by 10,128.9% in the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock worth $2,288,000 after acquiring an additional 1,265,910 shares during the last quarter. Susquehanna Portfolio Strategies LLC grew its stake in shares of Neumora Therapeutics by 74.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 72,106 shares of the company’s stock valued at $129,000 after purchasing an additional 30,866 shares during the last quarter. Finally, Millennium Management LLC raised its position in Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after purchasing an additional 1,608,266 shares during the last quarter. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Stock Down 3.1%

The firm’s 50-day moving average is $2.18 and its two-hundred day moving average is $2.06. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The stock has a market cap of $581.47 million, a P/E ratio of -2.37 and a beta of 3.20.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.